This report has been drafted under the responsibility of the WHO Secretariat, Department of
Essential Medicines and Health Products, Teams of Innovation, Access and Use and Policy,
Governance and Knowledge
(Expert Committee on Drug Dependence. Thirty-ninth Meeting
Geneva, 6-10 November 2017)
Summary:
Cannabidiol (CBD) is one of the naturally occurring cannabinoids found in cannabis plants. It
is a 21-carbon terpenophenolic compound which is formed following decarboxylation from a
cannabidiolic acid precursor, although it can also be produced synthetically, CBD can be converted to tetrahydrocannabinol (THC) under experimental conditions, however, this does not appear to occur to any significant effect in patients undergoing CBD
treatment.
In experimental models of abuse liability, CBD appears to have little effect on conditioned
place preference or intracranial self-stimulation. In an animal drug discrimination model CBD
failed to substitute for THC. In humans, CBD exhibits no effects indicative of any abuse or
dependence potential. There is unsanctioned medical use of CBD based products with oils, supplements, gums, and
high concentration extracts available online for the treatment of many ailments.
CBD is generally well tolerated with a good safety profile. Reported adverse effects may be as
a result of drug-drug interactions between CBD and patients’ existing medications.
Several countries have modified their national controls to accommodate CBD as a medicinal
product.
To date, there is no evidence of recreational use of CBD or any public health related problems
associated with the use of pure CBD.